adMare
News

adMare BioInnovations launches the BioInnovation Scientist (BIS) Program: Foundations and invites early-career science professionals to apply to be part of the inaugural cohort 

adMare Bioinnovations and PRiME Next-Generation Precision Medicine Collaborate to Translate Academic Research into Life Changing Therapeutics 

Canadian Alliance for Skills and Training in Life Sciences Partners with British Columbia Institute of Technology on New Biomanufacturing Training Facility

adMare BioInnovations Launches the adMare Tx Accelerator to Support Growth of Promising Early-stage Therapeutics Ventures across Canada

CASTL Announces Location for Quebec Biomanufacturing Training Facility
 

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) launches 2023 Short Course Calendar
 

Highlights of the Global Leaders Series with Dr. James Sabry

adMare Appoints Travis McCready to the Board of Directors

adMare BioInnovations and Medicine by Design Partner to Support Translation Priorities in the Toronto Life Sciences Ecosystem

Immugenia Obtains Pre-Seed Funding from adMare BioInnovations, ACET Capital, and Sherbrooke Innopole to Develop a Cancer Treatment Which Would Prevent Relapses

adMare BioInnovations Announces a Strong Cohort for Its Academy’s Executive Institute 2022-2023 Program

Discover the members of Cohort V of the Executive Institute

New partnership between Genome Canada and adMare BioInnovations to drive commercialization of genomics solutions in healthcare

Creating a stronger and more sustainable life sciences ecosystem in Canada.

Yes, Canada performed well throughout the pandemic, but at what cost?

Op-ed published in La Presse coauthered by Gordon C. McCauley, President & CEO of adMare BioInnovations, and his colleague Lesia Babiak, Head of Canada Government Affairs & Policy at Johnson & Johnson

adMare Appoints Patricia Gauthier to the Board of Directors

adMare BioInnovations welcomes Patricia Gauthier, President and General Manager of Moderna Canada, as the newest member of its Board of Directors. Patricia brings to adMare a wealth of leadership experience in global pharma and biotech.

Zucara Therapeutics’ Positive Proof-of-Concept Data Secures Continued Funding Ahead of Planned Phase 2 Clinical Trial of ZT-01

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Inversago Pharma Inc., a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) launches first series of hands-on training courses 

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) has launched their first series of hands-on training short courses to be delivered at the new CASTL Biomanufacturing Training Facility located in Charlottetown, Prince Edward Island.

adMare Porfolio Company Find Therapeutics Signs Licensing agreement to Develop a Promising New Therapy for Multiple Sclerosis and Other Demyelinating Diseases

Find Therapeutics Inc. (Montreal, Quebec) and SATT Conectus (Strasbourg, France) have signed an exclusive worldwide license to develop a promising therapy for Multiple Sclerosis (MS) and Optic Neuritis (ON) based on a new class of compounds.

adMare Portfolio Company FORUS Therapeutics Announces XPOVIO^® (selinexor) Is Authorized for Sale by Health Canada

FORUS Therapeutics Inc ("FORUS”), is pleased to announce that on May 31, 2022 XPOVIO^® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.

Anie Perrault joins adMare as Vice President, Public Affairs and Communications

adMare is pleased to announce the appointment of Anie Perrault, LL.L, ASC as Vice President, Public Affairs and Communications.

adMare Appoints Dr. Christine Allen as Vice-President, Ecosystem Development

Toronto May 18, 2022 – adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong…

adMare BioInnovations joins a $42m Series A financing in Domain Therapeutics

Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in…

adMare Portfolio Company, Zucara Therapeutics Secures Additional Funding for the Development of ZT-01

Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…

Join Us on May 30th, for the Official Opening of adMare’s Montreal Innovation Centre Expansion & BIOQuébec’s 2022 AGA

adMare BioInnovations and BIOQuébec cordially invite you to join your fellow Quebec life sciences leaders for a very special evening to celebrate the official opening of adMare’s new facility. Special guests will…

Read the newest issue of the adMare Quarterly newsletter – April 12, 2022

adMare Quarterly It has been a busy few months at adMare! From a transformative investment of $92M recently announced by the Minister of Innovation, Science and Industry at our Innovation…

Building Canada’s Life Sciences Industry on a Strong Foundation of Canadian Talent

Labour shortages are hitting virtually every Canadian sector, from coffee shops to car manufacturing – and life sciences is no exception. But what is exceptional about our industry is its…

adMare BioInnovations Collaborates with Accelerator Company, Molecular Forecaster Inc. on Computational Approaches to Drug Discovery

MONTREAL, QUEBEC, April 5, 2022 – Molecular Forecaster Inc. (MFI) is excited to announce a partnership with adMare BioInnovations (adMare) to deliver computer-aided drug design (CADD) resources to selected R&D…

Government of Canada Invests $92 million in adMare to help translate health research into innovative new therapies in Canada

GOVERNMENT OF CANADA RELEASE Government of Canada advances domestic life sciences sector by supporting Canadian companies, talent, and research and development March 30, 2022 – Vancouver, British Columbia –…

Listen to adMare’s President & CEO, Gordon C. McCauley on CGEn’s New Podcast, Synapsis

adMare’s President & CEO, Gordon C. McCauley speaks with Dr. Naveed Aziz on the first episode of CGEn’s new podcast, Synapsis, about the health sciences sector and what can be…

adMare supports Ukraine; Responds to Ministers Champagne and Duclos

Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health issued a statement on additional measures in response to Vladimir Putin’s…

Join Us For adMare’s Lunch & Learn: Building Talent with Amplitude Ventures March 17, 2022

The Amplitude Fellowship – Training the next generation of life science entrepreneurs Are you an outstanding life science focused PhD candidate, post doc, MD, or inventor? Do you want to…

Join Us For adMare’s Global Leaders Webinar Featuring Dr. Robert Langer April 19, 2022

adMare Global Leaders Webinar From Lab bench to clinic: How to solve global health challenges by developing new therapies through innovation and founding new companies Featuring Dr. Robert Langer adMare’s…

adMare Portfolio Company, Find Therapeutics, Appoints Dr. Philippe Douville as Chief Executive Officer

MONTREAL, Feb. 14, 2022 – Find Therapeutics Inc. (‘Find’) is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer. Dr. Douville brings to Find 25…

adMare Portfolio Company, Zucara Therapeutics Announces Publication of Preclinical Study

Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…

Inversago Pharma, an adMare Portfolio Company, Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update

MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses…

adMare Portfolio Company NIMIUM Therapeutics’ Research Breakthrough Shows Promise To Maintain Good Health As We Age

MONTREAL, Jan. 11, 2022 – New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives. The enzyme, Glycerol-3-Phosphate…

adMare Portfolio Company Neurasic Therapeutics Receives New Grant to Advance Non-Opioid Pain Treatment

Montréal – Québec – January 12th, 2022 –CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative…

adMare Quarterly

In this issue of adMare Quarterly, we are pleased to share our latest news on building companies, building ecosystems, and building talent to build the Canadian life sciences industry from sea to sea – along with Season’s Greetings and a look back on some 2021 highlights from adMare.

Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Toronto, Ontario, Canada [December…

Join Us for adMare’s Industry Builder Webinar Featuring Dr. Michel Bouvier – Jan. 17, 2022

Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better drugs? Join us for adMare’s Industry Builder Webinar Series, featuring Dr. Michel Bouvier. Dr. Bouvier…

adMare BioInnovations Announces Successful Applicants to 2021-2022 Executive Institute

Vancouver, BC and Montreal, QC (November 18, 2021) – adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of…

adMare BioInnovations and uOttawa Work Together to Translate University Research into Strong New Canadian Life Science Companies

Vancouver, BC, and Ottawa, ON (November 15, 2021) – adMare BioInnovations is pleased to announce a collaboration with the University of Ottawa to bring new resources and focus to the…

adMare BioInnovations and CASTL Partner to Build Canada’s Biomanufacturing Talent

Vancouver, BC and Charlottetown, PEI (November 9, 2021) – adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership…

adMare BioInnovations and District 3 Innovation partner to provide science-based Canadian startups more cohesive support to grow into industry leaders

MONTREAL, Quebec – November 2, 2021: District 3 Innovation Hub, an early-stage startup incubator located at Concordia University, and adMare BioInnovations, a Canadian life sciences leader that builds the industry…

adMare’s President & CEO Gordon C. McCauley is Appointed to BIOVECTRA Board of Directors

Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex…

adMare’s Accelerate Quebec Company, Molecular Forecaster, Continues Quest to Fast Track Drug Discovery with Two New Public-Private Partnerships

The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…

adMare Portfolio Company, Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker

MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL)…

adMare Portfolio Company BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

LAVAL, Quebec–(BUSINESS WIRE)–Sep. 13, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related…